Long-Term Incidence of Advanced Colorectal Neoplasia in Patients with Serrated Polyposis Syndrome: Experience in a Single Academic Centre

Daniel Rodríguez-Alcalde, Guillermo Castillo-López, Jorge López-Vicente, Luis Hernández, Mercedes Lumbreras-Cabrera, Diego Moreno-Sánchez, Daniel Rodríguez-Alcalde, Guillermo Castillo-López, Jorge López-Vicente, Luis Hernández, Mercedes Lumbreras-Cabrera, Diego Moreno-Sánchez

Abstract

Serrated polyposis syndrome (SPS) implies a slightly elevated risk of colorectal cancer (CRC) during endoscopic follow-up, but its natural course is still not well known. The main objective of this study was to describe the long-term risk of developing advanced neoplasia (AN) in these patients. Until October 2020, individuals who fulfilled 2010 WHO criteria I and/or III for SPS were retrospectively recruited. We selected those under endoscopic surveillance after resection of all lesions >3 mm in a high-quality colonoscopy. We excluded patients with total colectomy at diagnosis and those with any interval between colonoscopies >3.5 years. We defined AN as advanced serrated polyp (≥10 mm and/or with dysplasia), advanced adenoma, or CRC. In 109 patients, 342 colonoscopies were performed (median = 3, median interval = 1.8 years) during a median follow-up after colonic clearance of 5.0 years. Five-year cumulative incidences of AN were 21.6% globally, and 5.6%, 10.8%, and 50.8% in patients who fulfilled criterion I, III, and both, respectively (p < 0.001). No CRC was diagnosed and only 1 (0.9%) patient underwent surgery. In conclusion, cumulative incidences of AN could be lower than previously described, at least in patients who fulfil the 2010 WHO criterion III alone. Therefore, low-risk individuals might benefit from less stringent surveillance.

Keywords: advanced colorectal neoplasia; colorectal cancer; serrated polyp; serrated polyposis syndrome.

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Flow chart of patients during the study period.
Figure 2
Figure 2
Cumulative incidences of advanced adenoma, advanced serrated polyp, and advanced neoplasia within follow-up in patients with SPS. Percentages refer to cumulative incidence at five years.
Figure 3
Figure 3
Cumulative incidences of advanced neoplasia within follow-up in patients with SPS, according to 2010 WHO criteria. Percentages refer to cumulative incidence at five years.

References

    1. Bengoechea O., Martínez-Peñuela J.M., Larrínaga B., Valerdi J., Borda F. Hyperplastic polyposis of the colorectum and adenocarcinoma in a 24-year-old man. Am. J. Surg. Pathol. 1987;11:323–327. doi: 10.1097/00000478-198704000-00010.
    1. Jeevaratnam P., Cottier D.S., Browett P.J., Van De Water N.S., Pokos V., Jass J.R. Familial giant hyperplastic polyposis predisposing to colorectal cancer: A new hereditary bowel cancer syndrome. J. Pathol. 1996;179:20–25. doi: 10.1002/(SICI)1096-9896(199605)179:1<20::AID-PATH538>;2-C.
    1. McCann B.G. A case of metaplastic polyposis of the colon associated with focal adenomatous change and metachronous adenocarcinomas. Histopathology. 1988;13:700–702. doi: 10.1111/j.1365-2559.1988.tb02102.x.
    1. Jørgensen H., Mogensen A.M., Svendsen L.B. Hyperplastic polyposis of the large bowel. Three cases and a review of the literature. Scand. J. Gastroenterol. 1996;31:825–830. doi: 10.3109/00365529609010360.
    1. Place R.J., Simmang C.L. Hyperplastic-adenomatous polyposis syndrome. J. Am. Coll. Surg. 1999;188:503–507. doi: 10.1016/S1072-7515(99)00019-8.
    1. Boparai K.S., Mathus-Vliegen E.M.H., Koornstra J.J., Nagengast F.M., van Leerdam M., van Noesel C.J.M., Houben M., Cats A., van Hest L.P., Fockens P., et al. Increased colorectal cancer risk during follow-up in patients with hyperplastic polyposis syndrome: A multicentre cohort study. Gut. 2010;59:1094–1100. doi: 10.1136/gut.2009.185884.
    1. Snover D., Ahnen D.J., Burt R.W., Odze R.D. Serrated polyps of the colon and rectum and serrated (“hyperplastic”) polyposis. In: Bosman F.T., Carneiro F., Hruban R.H., Theise N.D., editors. WHO Classification of Tumours. Pathology and Genetics. Tumours of the Digestive System. 4th ed. International Agency for Research on Cancer (IARC); Lyon, France: 2010. pp. 160–165.
    1. Rosty C., Brosens L.A.A., Dekker E., Nagtegaal I.D. Serrated polyposis. In: Bosman F., Carneiro F., Hruban R., Theise N., editors. WHO Classification of Tumours of the Digestive System. 5th ed. International Agency for Research on Cancer (IARC); Lyon, France: 2019. pp. 532–534.
    1. Lage P., Cravo M., Sousa R., Chaves P., Salazar M., Fonseca R., Claro I., Suspiro A., Rodrigues P., Raposo H., et al. Management of Portuguese patients with hyperplastic polyposis and screening of at-risk first-degree relatives: A contribution for future guidelines based on a clinical study. Am. J. Gastroenterol. 2004;99:1779–1784. doi: 10.1111/j.1572-0241.2004.30178.x.
    1. Rubio C.A., Stemme S., Jaramillo E., Lindblom A. Hyperplastic polyposis coli syndrome and colorectal carcinoma. Endoscopy. 2006;38:266–270. doi: 10.1055/s-2006-925026.
    1. Chow E., Lipton L., Lynch E., D’Souza R., Aragona C., Hodgkin L., Brown G., Winship I., Barker M., Buchanan D., et al. Hyperplastic polyposis syndrome: Phenotypic presentations and the role of MBD4 and MYH. Gastroenterology. 2006;131:30–39. doi: 10.1053/j.gastro.2006.03.046.
    1. IJspeert J.E.G., Bevan R., Senore C., Kaminski M.F., Kuipers E.J., Mroz A., Bessa X., Cassoni P., Hassan C., Repici A., et al. Detection rate of serrated polyps and serrated polyposis syndrome in colorectal cancer screening cohorts: A European overview. Gut. 2017;66:1225–1232. doi: 10.1136/gutjnl-2015-310784.
    1. Biswas S., Ellis A.J., Guy R., Savage H., Madronal K., East J.E. High prevalence of hyperplastic polyposis syndrome (serrated polyposis) in the NHS bowel cancer screening programme. Gut. 2013;62:475. doi: 10.1136/gutjnl-2012-303233.
    1. Rivero-Sanchez L., Lopez-Ceron M., Carballal S., Moreira L., Bessa X., Serradesanferm A., Pozo A., Augé J.M., Ocaña T., Sánchez A., et al. Reassessment colonoscopy to diagnose serrated polyposis syndrome in a colorectal cancer screening population. Endoscopy. 2017;49:44–53. doi: 10.1055/s-0042-115640.
    1. Navarro M., González S., Iglesias S., Capellá G., Rodríguez-Moranta F., Blanco I. Síndrome de poliposis hiperplásica: Diversidad fenotípica y asociación a cáncer colorrectal. Med. Clin. (Barc) 2013;141:62–66. doi: 10.1016/j.medcli.2012.04.024.
    1. Leggett B.A., Devereaux B., Biden K., Searle J., Young J., Jass J. Hyperplastic polyposis: Association with colorectal cancer. Am. J. Surg. Pathol. 2001;25:177–184. doi: 10.1097/00000478-200102000-00005.
    1. Ferrández A., Samowitz W., DiSario J.A., Burt R.W. Phenotypic characteristics and risk of cancer development in hyperplastic polyposis: Case series and literature review. Am. J. Gastroenterol. 2004;99:2012–2018. doi: 10.1111/j.1572-0241.2004.30021.x.
    1. Rex D.K., Ahnen D.J., Baron J.A., Batts K.P., Burke C.A., Burt R.W., Goldblum J.R., Guillem J.G., Kahi C.J., Kalady M.F., et al. Serrated lesions of the colorectum: Review and recommendations from an expert panel. Am. J. Gastroenterol. 2012;107:1315–1329. doi: 10.1038/ajg.2012.161.
    1. Edelstein D.L., Axilbund J.E., Hylind L.M., Romans K., Griffin C.A., Cruz-Correa M., Giardiello F.M. Serrated polyposis: Rapid and relentless development of colorectal neoplasia. Gut. 2013;62:404–408. doi: 10.1136/gutjnl-2011-300514.
    1. Lieberman D.A., Rex D.K., Winawer S.J., Giardiello F.M., Johnson D.A., Levin T.R. Guidelines for colonoscopy surveillance after screening and polypectomy: A consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–857. doi: 10.1053/j.gastro.2012.06.001.
    1. Carballal S., Rodríguez-Alcalde D., Moreira L., Hernández L., Rodríguez L., Rodríguez-Moranta F., Gonzalo V., Bujanda L., Bessa X., Poves C., et al. Colorectal cancer risk factors in patients with serrated polyposis syndrome: A large multicentre study. Gut. 2016;65:1829–1837. doi: 10.1136/gutjnl-2015-309647.
    1. IJspeert J.E.G., Rana S.A.Q., Atkinson N.S.S., van Herwaarden Y.J., Bastiaansen B.A.J., van Leerdam M.E., Sanduleanu S., Bisseling T.M., Spaander M.C.W., Clark S.K., et al. Clinical risk factors of colorectal cancer in patients with serrated polyposis syndrome: A multicentre cohort analysis. Gut. 2017;66:278–284. doi: 10.1136/gutjnl-2015-310630.
    1. Rodríguez-Alcalde D., Carballal S., Moreira L., Hernández L., Rodríguez-Alonso L., Rodríguez-Moranta F., Gonzalo V., Bujanda L., Bessa X., Poves C., et al. High incidence of advanced colorectal neoplasia during endoscopic surveillance in serrated polyposis syndrome. Endoscopy. 2019;51:142–151. doi: 10.1055/a-0656-5557.
    1. Hazewinkel Y., Tytgat K.M.A.J., van Eeden S., Bastiaansen B., Tanis P.J., Boparai K.S., Fockens P., Dekker E. Incidence of colonic neoplasia in patients with serrated polyposis syndrome who undergo annual endoscopic surveillance. Gastroenterology. 2014;147:88–95. doi: 10.1053/j.gastro.2014.03.015.
    1. Bleijenberg A.G.C., IJspeert J.E.G., van Herwaarden Y.J., Carballal S., Pellisé M., Jung G., Bisseling T.M., Nagtegaal I.D., van Leerdam M.E., van Lelyveld N., et al. Personalised surveillance for serrated polyposis syndrome: Results from a prospective 5-year international cohort study. Gut. 2020;69:112–121. doi: 10.1136/gutjnl-2018-318134.
    1. van Leerdam M.E., Roos V.H., van Hooft J.E., Dekker E., Jover R., Kaminski M.F., Latchford A., Neumann H., Pellisé M., Saurin J.C., et al. Endoscopic management of polyposis syndromes: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy. 2019;51:877–895. doi: 10.1055/a-0965-0605.
    1. Bleijenberg A.G.C., IJspeert J.E.G., Hazewinkel Y., Boparai K.S., Oppeneer S.C., Bastiaansen B.A.J., Dekker E. The long-term outcomes and natural disease course of serrated polyposis syndrome: Over 10 years of prospective follow-up in a specialized center. Gastrointest. Endosc. 2020;92:1098–1107.e1. doi: 10.1016/j.gie.2020.04.068.
    1. MacPhail M.E., Thygesen S.B., Patel N., Broadley H.M., Rex D.K. Endoscopic control of polyp burden and expansion of surveillance intervals in serrated polyposis syndrome. Gastrointest. Endosc. 2019;90:96–100. doi: 10.1016/j.gie.2018.11.016.
    1. Parry S., Burt R.W., Win A.K., Aung Y.K., Woodall S., Arnold J., Clendenning M., Buchanan D.D., Price T.J., Rosty C., et al. Reducing the polyp burden in serrated polyposis by serial colonoscopy: The impact of nationally coordinated community surveillance. N. Z. Med. J. 2017;130:57–67.
    1. Hazewinkel Y., Tytgat K.M.A.J., van Leerdam M.E., Koornstra J.J., Bastiaansen B.A., van Eeden S., Fockens P., Dekker E. Narrow-band imaging for the detection of polyps in patients with serrated polyposis syndrome: A multicenter, randomized, back-to-back trial. Gastrointest. Endosc. 2015;81:531–538. doi: 10.1016/j.gie.2014.06.043.
    1. López-Vicente J., Rodríguez-Alcalde D., Hernández L., Riu Pons F., Vega P., Herrero Rivas J.M., Santiago García J., Salces Franco I., Bustamante Balén M., López-Cerón M., et al. Panchromoendoscopy Increases Detection of Polyps in Patients with Serrated Polyposis Syndrome. Clin. Gastroenterol. Hepatol. 2019;17:2016–2023.e6. doi: 10.1016/j.cgh.2018.10.029.
    1. Rivero-Sánchez L., López Vicente J., Hernandez Villalba L., Puig I., Arnau-Collell C., Moreno L., Díaz M., Rodriguez de Miguel C., Ocaña T., Moreira L., et al. Endocuff-assisted colonoscopy for surveillance of serrated polyposis syndrome: A multicenter randomized controlled trial. Endoscopy. 2019;51:637–645. doi: 10.1055/a-0925-4956.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere